Authorization

argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update

- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)- Pre-approval access program opened in U.S. and Europe for eligible gMG patientsA A A A A A A A A A A A - Management to host conference call today at 2:30 pm CEST (8:30 am ET) -March 4, 2021

Breda, the Netherlands a?? argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today reported financial results for the full year 2020 and provided a fourth quarter business update.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2021    »
ПнВтСрЧтПтСбВс
 1234
567891011
12131415161718
19202122232425
2627282930